Standout Papers

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Ant... 1996 2026 2006 2016 2.1k
  1. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (1999)
    Melody Cobleigh, Charles L. Vogel et al. Journal of Clinical Oncology
  2. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2002)
    Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology
  3. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996)
    José Baselga, Debu Tripathy et al. Journal of Clinical Oncology
  4. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998)
    Mark D. Pegram, A. Lipton et al. Journal of Clinical Oncology
  5. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (2019)
    Seock‐Ah Im, Yen‐Shen Lu et al. New England Journal of Medicine
  6. Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment (2017)
    Heather Greenlee, Melissa J. DuPont‐Reyes et al. CA A Cancer Journal for Clinicians
  7. Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update (2024)
    Julienne E. Bower, Christina Lacchetti et al. Journal of Clinical Oncology

Immediate Impact

17 by Nobel laureates 7 from Science/Nature 142 standout
Sub-graph 1 of 18

Citing Papers

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
21 intermediate papers

Works of Debu Tripathy being referenced

Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment
2021
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
2019 Standout
and 10 more

Author Peers

Author Last Decade Papers Cites
Debu Tripathy 10360 3594 2940 4170 4129 414 15.4k
Evandro de Azambuja 10394 3489 4530 2482 3047 346 14.9k
Aditya Bardia 10465 5194 4867 1682 3865 468 15.3k
Julie R. Gralow 12174 4063 5389 4416 3892 277 19.8k
Melody Cobleigh 10293 2780 3687 2943 4216 130 14.4k
Hans Wildiers 7289 3163 3358 1592 2679 382 14.1k
Alberto Ocaña 7114 2462 2453 1626 3696 296 12.0k
John Crown 12728 4664 5824 2293 7262 413 19.6k
Sabino De Placido 7699 4412 3698 1608 4332 376 13.7k
Nancy U. Lin 10838 7494 3908 2226 3343 368 16.5k
John R. Mackey 14473 4467 3908 1835 5741 328 23.9k

All Works

Loading papers...

Rankless by CCL
2026